What is the latest PGHL stock price?
The latest stored price for PGHL is Rs 5,503.50 as of 2026-09-18.
gimli
PGHL stock AI analysis
PGHL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
PROCTER & GAMBLE HEALTH L is a small-cap stock in Healthcare. This Gimli page shows the latest available PGHL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹5,503.50
1W return
+1.44%
1M return
-5.73%
3M return
-12.79%
6M return
+11.41%
1Y return
-12.16%
Market cap
₹9,135.48 cr
PE
25.60
PB
17.42
ROE
+67.16%
ROCE
+66.84%
RSI
35.66
Turnover
₹3.17 cr
Why it can matter in screens
- Momentum: PGHL is below 50DMA, below 200DMA; RSI is 35.66.
- Returns: 1D +1.27%, 1W +1.44%, 1M -5.73%, 3M -12.79%, 1Y -12.16%.
- Trend levels: 52W high ₹6,975.00, 52W low ₹5,302.50, off high -21.10%.
- Liquidity: latest turnover is ₹3.17 cr; volume vs 20D is +0.62%.
- Valuation/profitability: PE 25.60, PB 17.42, ROE +67.16%, ROCE +66.84%.
- Growth: 3Y sales CAGR +9.85%, 3Y profit CAGR +27.56%.
Quick Answers
Is PGHL above its 50DMA and 200DMA?
PGHL is below 50DMA, below 200DMA. The latest 50DMA is 6,111.08 and the latest 200DMA is 5,633.64.
What are PGHL PE, ROE and ROCE?
PGHL has PE 25.60, ROE +67.16%, and ROCE +66.84% in Gimli's latest available snapshot.
How has PGHL performed recently?
PGHL has returned -5.73% over 1 month, -12.79% over 3 months, and -12.16% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 367.59 cr | 103.48 cr | 96.15 cr | 57.92 |
| 2026-03-31 | 370.45 cr | 139.59 cr | 94.60 cr | 56.99 |
| 2025-12-31 | 373.86 cr | 114.82 cr | 77.59 cr | 46.74 |
| 2025-09-30 | 324.92 cr | 125.22 cr | 88.54 cr | 53.54 |
| 2025-06-30 | 338.74 cr | 94.37 cr | 66.18 cr | 39.87 |
| 2025-03-31 | 310.99 cr | 84.03 cr | 61.18 cr | 36.86 |
| 2024-12-31 | 309.77 cr | 127.39 cr | n/a | nan |
| 2024-09-30 | 313.41 cr | 117.32 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,407.97 cr | 474.00 cr | 326.91 cr | 196.94 |
| 2025-03-31 | 944.52 cr | 328.74 cr | 234.41 cr | 141.00 |
| 2024-06-30 | 1,129.49 cr | 301.44 cr | 200.98 cr | 121.00 |
| 2024-03-31 | 1,166.89 cr | 301.44 cr | 200.98 cr | 121.00 |
| 2023-06-30 | 1,205.86 cr | 343.07 cr | 229.47 cr | 138.00 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 841.35 cr | 177.24 cr | 9.29 cr | 524.55 cr |
| 2024-06-30 | 794.36 cr | 238.50 cr | 9.56 cr | 538.24 cr |
| 2023-06-30 | 1,101.19 cr | 435.05 cr | 12.00 cr | 750.89 cr |
| 2022-06-30 | 888.12 cr | 319.40 cr | 2.83 cr | 616.49 cr |
| 2021-06-30 | 986.16 cr | 464.05 cr | 7.61 cr | 703.71 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 337.79 cr | 322.28 cr | n/a |
| 2024-06-30 | 228.29 cr | 206.56 cr | n/a |
| 2023-06-30 | 236.00 cr | 193.52 cr | n/a |
| 2022-06-30 | 169.52 cr | 131.60 cr | n/a |
| 2021-06-30 | 247.26 cr | 194.68 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +51.82% | +6.33% | +12.44% | +9.05% | +29.42% | +0.00% |
| 2026-03-31 | +51.82% | +6.20% | +13.67% | +10.20% | +28.31% | +0.00% |
| 2025-12-31 | +51.82% | +6.97% | +13.84% | +10.48% | +27.37% | +0.00% |
| 2025-09-30 | +51.82% | +7.24% | +13.91% | +10.56% | +27.04% | +0.00% |
| 2025-06-30 | +51.82% | +6.99% | +14.16% | +10.65% | +27.03% | +0.00% |
| 2025-03-31 | +51.82% | +6.87% | +14.21% | +10.54% | +27.11% | +0.00% |
| 2024-12-31 | +51.82% | +7.02% | +14.71% | +10.64% | +26.46% | +0.00% |
| 2024-09-30 | +51.82% | +6.61% | +14.84% | +10.45% | +26.74% | +0.00% |
| 2024-06-30 | +51.82% | +6.40% | +14.55% | +10.19% | +27.23% | +0.00% |
| 2024-03-31 | +51.82% | +6.24% | +13.73% | +9.86% | +28.21% | +0.00% |
| 2023-12-31 | +51.82% | +7.59% | +12.67% | +8.98% | +27.92% | +0.00% |
| 2023-09-30 | +51.82% | +7.38% | +12.31% | +8.41% | +28.49% | +0.00% |
| 2023-06-30 | +51.82% | +7.15% | +12.30% | +8.10% | +28.74% | n/a |
| 2023-03-31 | +51.82% | +6.72% | +12.31% | +7.34% | +29.15% | +0.00% |
| 2022-12-31 | +51.82% | +6.33% | +12.43% | +7.28% | +29.42% | +0.00% |
| 2022-09-30 | +51.82% | +6.05% | +12.62% | +6.90% | +29.51% | n/a |
| 2022-06-30 | +51.82% | +0.00% | +14.54% | n/a | n/a | +0.00% |
| 2022-03-31 | +51.82% | +0.00% | +14.48% | n/a | n/a | +0.00% |
| 2021-12-31 | +51.82% | +0.00% | +14.50% | n/a | n/a | +0.00% |
| 2021-09-30 | +51.82% | +0.00% | +14.24% | n/a | n/a | n/a |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze PROCTER & GAMBLE HEALTH L with valuation, momentum and industry peers
- Compare PGHL with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare PGHL with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.